Cargando…

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data

SIMPLE SUMMARY: Targeting angiogenesis, the formation of new blood vessels, is an integral part of many cancer treatments, including colorectal cancer. The overall clinical benefit is well documented but modest. It has been an ongoing task for the last decade to isolate patient and tumor characteris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hansen, Torben Frøstrup, Qvortrup, Camilla, Pfeiffer, Per
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957514/ https://www.ncbi.nlm.nih.gov/pubmed/33804554 http://dx.doi.org/10.3390/cancers13051031

Ejemplares similares

How to select colorectal cancer patients for personalized therapy
por: Pfeiffer, Per, et al.
Publicado: (2019)

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients
por: Pfeiffer, Per, et al.
Publicado: (2009)

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example
por: Winther, Stine Braendegaard, et al.
Publicado: (2016)

How to select cancer patients for immunotherapy
por: Pfeiffer, Per, et al.
Publicado: (2021)

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
por: Dizdarevic, Edina, et al.
Publicado: (2022)

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
por: Trabjerg, Natacha Dencker, et al.
Publicado: (2019)

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
por: Hansen, Torben Frøstrup, et al.
Publicado: (2012)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
por: Siesing, Christina, et al.
Publicado: (2017)

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
por: Paulsen, Niels Herluf, et al.
Publicado: (2022)

Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer—A Systematic Review
por: Wen, Sara Witting Christensen, et al.
Publicado: (2022)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study
por: Hansen, Torben Frøstrup, et al.
Publicado: (2015)

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
por: Eriksen, Martina, et al.
Publicado: (2022)

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
por: Hansen, Torben Frøstrup, et al.
Publicado: (2017)

Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis
por: Borg, Morten, et al.
Publicado: (2023)

Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I–III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol
por: Justesen, Tobias Freyberg, et al.
Publicado: (2023)

NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
por: Raunkilde, Louise, et al.
Publicado: (2022)

Biomarkers of Angiogenesis in Colorectal Cancer
por: Mousa, Luay, et al.
Publicado: (2015)

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer
por: Otsu, Satoshi, et al.
Publicado: (2023)

A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
por: Tarpgaard, Line S., et al.
Publicado: (2016)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
por: Ansari, Mohammad Javed, et al.
Publicado: (2022)

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
por: Sorbye, Halfdan, et al.
Publicado: (2015)

NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Wen, Sara Witting Christensen, et al.
Publicado: (2023)

Angiogenesis Factors Involved in the Pathogenesis of Colorectal Cancer
por: MIHALACHE, A., et al.
Publicado: (2014)

Angiogenesis inhibitors in the treatment of prostate cancer
por: Hwang, Clara, et al.
Publicado: (2010)

Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone
por: Cavalli-Björkman, N, et al.
Publicado: (2012)

A review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and pancreatic cancers
por: Rudno-Rudzińska, Julia, et al.
Publicado: (2017)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
por: Sun, Weijing
Publicado: (2012)

Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
por: Wang, Ying-Qing, et al.
Publicado: (2013)

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
por: Jensen, Lars Henrik, et al.
Publicado: (2019)

Re‐exposure to immunotherapy in metastatic colon cancer: A case report
por: Hamre, Tonje Riise, et al.
Publicado: (2021)

MicroRNA-200b is downregulated in colon cancer budding cells
por: Knudsen, Kirsten Nguyen, et al.
Publicado: (2017)

Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer
por: Salem, Abdelhakim, et al.
Publicado: (2021)

Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
por: Jensen, Lars Henrik, et al.
Publicado: (2023)

Evaluation of Angiogenesis in Colorectal Cancer
por: DELIU, I.C., et al.
Publicado: (2015)

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2021)

Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors
por: Mira, Alessia, et al.
Publicado: (2017)

The Impact of Patient Characteristics and Tumor Biology on the Accuracy of Preoperative Staging of Colon Cancer in Denmark. A Nationwide Cohort Study
por: Pedersen, Malene Roland V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g93h6brcv3rp7lck3r56hkd8bu